ArticleEmerging microbes & infections2020
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.
Article in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 303 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
303 citing papers in PubMed, 3 syntheses or guidelines pooled it, 535 citations in OpenAlex.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data.Cancer letters · 2021Pooled it
- What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 1).Annals of internal medicine · 2021Guideline
- Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination.Scientific reports · 2023Trial
- COVID-19 serology in nephrology healthcare workers.Wiener klinische Wochenschrift · 2021Trial
- Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients.Journal of immunological methods · 2021Trial
- Differential Binding and Neutralising Antibody Responses Across COVID-19 Severity in a Saudi Multicentre Cohort.Viruses · 2026Article
- Total plasma N-glycomic patterns of COVID-19 disease.Glycoconjugate journal · 2026Article
- Symptom burden, viral load, and antibody response to ancestral SARS-CoV-2 strain [D614G] in an outpatient household cohort.PloS one · 2026Article
- Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters.Communications biology · 2025Article
- Cytokine and Antibody Isotype Responses in Vaccinated Healthcare Workers with SARS-CoV-2 Breakthrough Infections.Viruses · 2025Article
- Titers of IgG, IgM, and IgA Against SARS-CoV-2 in Healthcare Workers from a General Hospital in Mexico City.Diseases (Basel, Switzerland) · 2025Article
- Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity.Journal of medical microbiology · 2025Article
- Advances in Surrogate Neutralization Tests for High-Throughput Screening and the Point-of-Care.Analytical chemistry · 2025Review
- Genetic diversity of the immunoglobulin heavy chain locus in cohorts of patients affected with SARS-CoV-2.Human genomics · 2025Article
- A multicentre study comparing post-mortem SARS-CoV-2 antibody testing in Cape Town mortuaries.Southern African journal of infectious diseases · 2025Article
- CXCL9 and CXCL10 support the exacerbated humoral response in recovered COVID-19 patients who developed acute respiratory distress syndrome by promoting plasma cell differentiation, whereas CXCL9 also induces CD40L and CXCR3 upregulation on T helper cells.Frontiers in immunology · 2025Article
- Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees.The Libyan journal of medicine · 2024Article
- Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.Pathogens (Basel, Switzerland) · 2024Review
- Article
243 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging COVID-19 caused by SARS-CoV-2 infection poses severe challenges to global public health. Serum antibody testing is becoming one of the critical methods for the diagnosis of COVID-19 patients. We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and spike (S) protein after symptom onset in the intensive care unit (ICU) and non-ICU patients. 130 blood samples from 38 COVID-19 patients were collected. The levels of IgM and IgG specific to N and S protein were detected by ELISA. A series of blood samples were collected along the disease course from the same patient, including 11 ICU patients and 27 non-ICU patients for longitudinal analysis. N and S specific IgM and IgG (N-IgM, N-IgG, S-IgM, S-IgG) in non-ICU patients increased after symptom onset. N-IgM and S-IgM in some non-ICU patients reached a peak in the second week, while N-IgG and S-IgG continued to increase in the third week. The combined detection of N and S specific IgM and IgG could identify up to 75% of SARS-CoV-2 infected patients in the first week. S-IgG was significantly higher in non-ICU patients than in ICU patients in the third week. In contrast, N-IgG was significantly higher in ICU patients than in non-ICU patients. The increase of S-IgG positively correlated with the decrease of C-reactive protein (CRP) in non-ICU patients. N and S specific IgM and IgG increased gradually after symptom onset and can be used for detection of SARS-CoV-2 infection. Analysis of the dynamics of S-IgG may help to predict prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.